3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Lymphoid
2
Conditions
Breast Neoplasms
8
Triple Negative Breast Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
HER2-positive Breast Cancer
2
Stomach Neoplasms
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
Colorectal Neoplasms
1
Brain Neoplasms
1
Anatomic Stage II Breast Cancer AJCC v8
1
Adenocarcinoma
1
Interventions
Cyclophosphamide
28
Rituximab
23
fludarabine
14
fludarabine phosphate
12
Specimen Handling
11
obinutuzumab
10
ibrutinib
10
Magnetic Resonance Spectroscopy
10
Prednisone
8
Doxorubicin
8
tocilizumab
7
polatuzumab vedotin
7
X-Rays
7
Whole-Body Irradiation
7
Phantoms, Imaging
7
Mycophenolic Acid
7
Etoposide
7
Biopsy
7
venetoclax
6
glofitamab
6
Melphalan
6
Lenalidomide
6
Bendamustine Hydrochloride
6
pirtobrutinib
5
acalabrutinib
5
Vincristine
5
Peripheral Blood Stem Cell Transplantation
5
Nuclear Medicine Department, Hospital
5
Nivolumab
5
Gemcitabine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
tucatinib
×
90 days
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled
NCT03297606
2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2
Recruiting
720 enrolled